endostatin + platinum-based chemotherapy

**Endostatin + platinum-based chemotherapy** is a combination regimen comprised of recombinant human endostatin (also known as Endostar, a biologic angiogenesis inhibitor) together with a platinum-based chemotherapy agent such as cisplatin, carboplatin, or oxaliplatin. **Endostatin** targets the tumor microenvironment by inhibiting angiogenesis, normalizing aberrant vascular structures, and blocking growth factor signaling related to neovascularization; platinum agents induce DNA damage, triggering cancer cell apoptosis. This combination is utilized primarily in advanced non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and triple-negative breast cancer (TNBC), showing improved progression-free and overall survival rates in clinical studies, with generally manageable toxicity profiles. In China, the recombinant human endostatin Endostar is approved for NSCLC in combination with chemotherapy[1][2][3][4]. The mechanism reflects **synergistic antiangiogenic and cytotoxic antineoplastic action**.

Brand names

Endostar + platinum-based chemotherapy

Other names

recombinant human endostatin + platinum-based chemotherapyendostatin + platinum-etoposide